Nomikos G G, Damsma G, Wenkstern D, Fibiger H C
Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Eur J Pharmacol. 1991 Mar 19;195(1):63-73. doi: 10.1016/0014-2999(91)90382-z.
There is accumulating evidence that some antidepressant treatments can increase the functional output of the meso-accumbens dopaminergic system. For example, chronic administration of tricyclic antidepressant drugs such as imipramine and desipramine (DMI) enhances the locomotor stimulant effects of d-amphetamine. Subsensitivity of inhibitory dopamine (DA) autoreceptors and supersensitivity of postsynaptic DA receptor mechanisms are among the mechanisms that have been suggested to underlie these observations. The present experiments investigated the effects of acute and chronic DMI treatment on interstitial DA concentrations in the nucleus accumbens and striatum using in vivo microdialysis in awake freely moving rats (48 h following implantation of a microdialysis probe). Neither acute (5 mg/kg b.i.d. for 2 days followed by 72 h withdrawal) nor chronic (5 mg/kg b.i.d. for 21 days followed by 72 h withdrawal) DMI influenced the ability of apomorphine (25 micrograms/kg s.c.) to decrease extracellular concentrations of DA or its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the nucleus accumbens. In contrast, d-amphetamine (1.5 mg/kg s.c.)-induced increases in extracellular DA were significantly enhanced in the nucleus accumbens of the chronic but not the acute DMI group. This effect was at least partially regionally selective, as significant effects were not observed in the striatum. In accordance with previous reports, the locomotor stimulant effects of d-amphetamine were also enhanced in the chronic DMI groups. DMI itself failed to alter the interstitial concentrations of DA and its metabolites in the nucleus accumbens of the control and chronic DMI groups. These results provide in vivo neurochemical confirmation that chronically administered DMI does not produce DA autoreceptor subsensitivity. They also demonstrate that chronic DMI-induced increases in the locomotor stimulant effects of d-amphetamine are accompanied by a selective potentiation of the effects of this stimulant on interstitial DA concentrations in the nucleus accumbens.
越来越多的证据表明,某些抗抑郁治疗可增加中脑伏隔核多巴胺能系统的功能输出。例如,长期给予三环类抗抑郁药如丙咪嗪和地昔帕明(DMI)可增强右旋苯丙胺的运动兴奋作用。抑制性多巴胺(DA)自身受体的亚敏感性和突触后DA受体机制的超敏感性是被认为是这些观察结果的潜在机制。本实验使用清醒自由活动大鼠(植入微透析探针48小时后)的体内微透析技术,研究了急性和慢性DMI治疗对伏隔核和纹状体中细胞外DA浓度的影响。急性(5mg/kg,每日两次,持续2天,然后停药72小时)或慢性(5mg/kg,每日两次,持续21天,然后停药72小时)DMI均不影响阿扑吗啡(25μg/kg,皮下注射)降低伏隔核中DA或其代谢物3,4-二羟基苯乙酸(DOPAC)和高香草酸(HVA)细胞外浓度的能力。相反,在慢性而非急性DMI组的伏隔核中,右旋苯丙胺(1.5mg/kg,皮下注射)诱导的细胞外DA增加显著增强。这种效应至少部分具有区域选择性,因为在纹状体中未观察到显著影响。与先前的报道一致,慢性DMI组中右旋苯丙胺的运动兴奋作用也增强。DMI本身未能改变对照组和慢性DMI组伏隔核中DA及其代谢物的细胞外浓度。这些结果提供了体内神经化学证据,表明长期给予DMI不会产生DA自身受体亚敏感性。它们还表明,慢性DMI诱导的右旋苯丙胺运动兴奋作用增强伴随着该兴奋剂对伏隔核中细胞外DA浓度影响的选择性增强。